Pentadeca Arginate / PDA 10mg

1. 1

   Clean the rubber stoppers of both the PDA vial and the bacteriostatic water container using sterile alcohol swabs and allow them to dry completely.

2. 2

   Verify through supplier documentation whether the 10 mg label reflects gross salt mass or net peptide content to confirm dose calculations.

3. 3

   Draw exactly 3.0 mL of bacteriostatic water into a reconstitution syringe using an appropriate gauge needle.

4. 4

   Introduce the diluent slowly into the vial by directing the stream along the interior glass wall to avoid turbulent foaming.

5. 5

   Swirl and roll the vial gently between the palms until the lyophilized cake is fully dissolved, strictly avoiding vigorous agitation.

6. 6

   Inspect the clear solution for particulates and place the reconstituted vial immediately into refrigeration at 2 to 8 °C.

Overview

Pentadeca Arginate, commonly referred to in research circles as PDA, consists of the synthetic 15-amino-acid peptide BPC-157 paired with an L-arginine counterion rather than the traditional acetate salt. Derived originally from human gastric secretions, the fundamental peptide sequence is identical to standard BPC-157. The formulation gained prominence as a potential alternative salt form aimed at theoretically modulating physicochemical characteristics, though published empirical literature evaluating this specific arginate pairing remains non-existent in formal indices. Preclinical interest stems directly from broader investigations into BPC-157, which indicate notable regenerative properties across several animal injury models. Laboratory assessments in rodents have demonstrated accelerated repair of transected muscles, ligaments, and tendons, including historically difficult interfaces such as osteotendinous and myotendinous junctions. Additionally, the peptide has been evaluated for cytoprotective and anti-ulcerogenic qualities along the gastrointestinal tract, underpinned by pro-angiogenic activity without reliance on external scaffolding. Despite widespread anecdotal adoption and marketing claims proposing enhanced oral stability or superior systemic bioavailability, rigorous clinical validation is currently missing. The overall human clinical record is limited to small, uncontrolled exploratory trials of the base peptide, with formal randomized controlled studies only recently emerging. Investigators working with PDA should note that analytical certificates of analysis are necessary to verify whether stated vial weights reflect total salt mass or net active peptide content.

1. 1.Sikiric et al., Inflammopharmacology, 2006 — Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease
2. 2.Mateescu et al., Pharmaceutics, 2026 — BPC-157 as an investigational peptide therapeutic and translational development barriers
3. 3.Japjec et al., Biomedicines, 2021 — Stable gastric pentadecapeptide BPC 157 as a therapy for myotendinous junction healing in rats
4. 4.Matek et al., Pharmaceutics, 2025 — BPC 157 therapy after surgical detachment of the quadriceps muscle for reattachment in rats
5. 5.Matek et al., Pharmaceuticals, 2026 — Tendon, ligament, and muscle injury and junction repair perspectives with BPC 157
6. 6.Sikiric et al., World Journal of Gastroenterology, 2022 — Cytoprotective gastric pentadecapeptide BPC 157 in major vessel occlusion and ischemia-reperfusion
7. 7.Sikiric et al., Current Pharmaceutical Design, 2017 — Gastrointestinal stress, nitric oxide signaling, and safety profile of BPC 157

Peptide VialView

Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.